The other advantage in hMSCs is that the proliferation capacity reduces dramatically following the differentiation induction phase and ceases to proliferate following transplantation as no Ki67 protein was detected from the grafts, which is different from the embryonic stem cells that form teratoma in recipients [42]. The gene discussed is MKI67; the disease is teratoma.